Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • kjaja
    Member
    • Aug 2011
    • 58

    #1

    question on predicting the function of a variant

    Hi All,

    I have a question in prediction of function for mutations. Is it better to use Polyphen2 or SIFT score. I came across a mutation that has a low SIFT score (0.01) but when I used Polyphen, it was predicted to be “benign”. Is it better to go with SIFT or Polyphen2 and how do they differ.

    I appreciate your help
  • Heisman
    Senior Member
    • Dec 2010
    • 534

    #2
    This is something that has not been solved well. If you use ANNOVAR to annotate your variants, it will query against multiple databases (newest version does PolyPhen2, SIFT, LRT, PhyloP, MutationTaster, all according to the dbNSFP paper http://onlinelibrary.wiley.com/doi/1...21517/abstract), as well as the GERP++ score and it will tell you if the variant is present in dbSNP135, as well as the frequency it is present in the 1000 genomes project and the Exome Variant Server.

    Now, how do you interpret that? I once for fun took all of the SNPs in dbSNP135 that were stated to be confirmed damaging or confirmed non-damaging and ran them through ANNOVAR to compare all of them. Pretty much none of the metrics showed a big enough distinction to be useful, with the exception of PolyPhen2 and especially MutationTaster. So I would say those are the best. HOWEVER, I do not know if the SNPs I was looking at were included in the training sets for those two algorithms; if they were than this was useless.

    So, I would trust PolyPhen2 over SIFT, but I wouldn't have much confidence in either.

    Comment

    • dlgoode
      Junior Member
      • Dec 2011
      • 3

      #3
      You might be interested in this paper that recently appeared in Bioinformatics:

      Performance of computational tools in evaluating the functional impact of laboratory-induced amino acid mutations

      http://bioinformatics.oxfordjournals...ef-corresp-1-1

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
        by SEQadmin2



        Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

        Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
        ...
        10-14-2026, 09:55 AM
      • SEQadmin2
        New Genomics Technologies Take Aim at Long-Standing Limits
        by SEQadmin2


        Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

        We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
        ...
        09-28-2026, 10:25 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, Yesterday, 11:13 AM
      0 responses
      18 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, Yesterday, 10:48 AM
      0 responses
      18 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-15-2026, 10:52 AM
      0 responses
      36 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-14-2026, 05:39 AM
      0 responses
      42 views
      0 reactions
      Last Post SEQadmin2  
      Working...